Last reviewed 2026-04-23 · How we verify

Placebo - IR Prednisone

This is a placebo control arm in a clinical trial; it contains no active pharmaceutical ingredient and produces no pharmacological effect.

This is a placebo control arm in a clinical trial; it contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trial of immediate-release prednisone.

At a glance

Mechanism of action

Placebo serves as the control comparator in Phase 3 trials to establish efficacy of the active prednisone arm through blinded comparison. Any observed effects in the placebo group reflect natural disease progression, regression to the mean, or nocebo/placebo psychological effects rather than drug action. Prednisone itself is a glucocorticoid that suppresses immune function and inflammation, but the placebo formulation is inert.

Approved indications

• Control arm in Phase 3 clinical trial of immediate-release prednisone

Common side effects

No common side effects on file.

Key clinical trials

• Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (PHASE4)
• Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo - IR Prednisone CI brief — competitive landscape report
• Placebo - IR Prednisone updates RSS · CI watch RSS
• Merck KGaA, Darmstadt, Germany portfolio CI